The Latest Analyst Ratings for Bellerophon Therapeutics
BenzingaJun 6, 2023 17:01 ET
HC Wainwright & Co. Maintains Buy on Bellerophon Therapeutics, Lowers Price Target to $2
BenzingaJun 6, 2023 06:35 ET
HC Wainwright & Co. Reinstates Buy on Bellerophon Therapeutics, Maintains $30 Price Target
BenzingaMay 17, 2023 06:16 ET
Laidlaw & Co. Initiates Coverage On Bellerophon Therapeutics With Buy Rating, Announces Price Target of $35
BenzingaMay 9, 2023 10:07 ET
HC Wainwright & Co. Reiterates Buy on Bellerophon Therapeutics, Maintains $30 Price Target
BenzingaApr 4, 2023 06:26 ET
Watching Baylor BioSciences; Brookline Capital Reiterates Buy Rating, Sets $19 Price Target
Benzinga Real-time NewsJan 5, 2023 11:42 ET
No Data
No Data